Fennec Pharmaceuticals Expects To Receive Complete Response Letter From The FDA For Its New Drug Application For PEDMARK To Prevent Ototoxicity Associated With Cisplatin In Pediatric Patients With Localized, Non-Metastatic, Solid Tumors